{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:23:52Z","timestamp":1793939032363,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["1908085QH315"],"award-info":[{"award-number":["1908085QH315"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-022-03227-z","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T03:29:52Z","timestamp":1655090992000},"page":"2125-2131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Simvastatin inhibits prostatic hyperplasia in rats with metabolic syndrome"],"prefix":"10.1007","volume":"54","author":[{"given":"Yi ming","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue chun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-2655","authenticated-orcid":false,"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"5","key":"3227_CR1","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1080\/13685538.2018.1541979","volume":"23","author":"SS Cakir","year":"2020","unstructured":"Cakir SS, Ozcan L, Polat EC et al (2020) Statins are effective in the treatment of benign prostatic hyperplasia with metabolic syndrome. Aging Male 23(5):538\u2013543","journal-title":"Aging Male"},{"issue":"3","key":"3227_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.urology.2013.03.047","volume":"82","author":"YW Park","year":"2013","unstructured":"Park YW, Kim SB, Kwon H et al (2013) The relationship between lower urinary tract symptoms\/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 82(3):674\u2013679","journal-title":"Urology"},{"issue":"2","key":"3227_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000357760","volume":"93","author":"X Zhang","year":"2014","unstructured":"Zhang X, Zeng X, Liu Y et al (2014) Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int 93(2):214\u2013219","journal-title":"Urol Int"},{"issue":"6","key":"3227_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/pros.23962","volume":"80","author":"BW Xia","year":"2020","unstructured":"Xia BW, Zhao SC, Chen ZP et al (2020) The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume. Prostate 80(6):481\u2013490","journal-title":"Prostate"},{"issue":"4","key":"3227_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s11255-018-1826-9","volume":"50","author":"C Xu","year":"2018","unstructured":"Xu C, Xu Y, Shen Z et al (2018) Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia. Int Urol Nephrol 50(4):611\u2013617. https:\/\/doi.org\/10.1007\/s11255-018-1826-9","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"3227_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1097\/01.ju.0000149130.06055.f2","volume":"173","author":"EV Vykhovanets","year":"2005","unstructured":"Vykhovanets EV, Resnick MI, Marengo SR (2005) The healthy rat prostate contains high levels of natural killer-like cells and unique subsets of CD4+ helper-inducer T cells: implications for prostatitis. J Urol 173(3):1004\u20131010","journal-title":"J Urol"},{"key":"3227_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","volume":"88","author":"CR Sirtori","year":"2014","unstructured":"Sirtori CR (2014) The pharmacology of statins. Pharmacol Res 88:3\u201311. https:\/\/doi.org\/10.1016\/j.phrs.2014.03.002","journal-title":"Pharmacol Res"},{"issue":"7","key":"3227_CR8","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/labinvest.3780115","volume":"80","author":"M Romano","year":"2000","unstructured":"Romano M, Diomede L, Sironi M et al (2000) Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 80(7):1095\u20131100","journal-title":"Lab Invest"},{"issue":"17","key":"3227_CR9","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1161\/01.CIR.0000092949.67153.74","volume":"108","author":"K Shimizu","year":"2003","unstructured":"Shimizu K, Aikawa M, Takayama K et al (2003) Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 108(17):2113\u20132120","journal-title":"Circulation"},{"issue":"12","key":"3227_CR10","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00345-015-1550-3","volume":"33","author":"X Zhang","year":"2015","unstructured":"Zhang X, Zeng X, Dong L et al (2015) The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome. World J Urol 33(12):2071\u20132077","journal-title":"World J Urol"},{"issue":"22","key":"3227_CR11","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e164","volume":"35","author":"GE Chung","year":"2020","unstructured":"Chung GE, Yim JY, Kim D et al (2020) Nonalcoholic fatty liver disease is associated with benign prostate hyperplasia. J Korean Med Sci 35(22):e164","journal-title":"J Korean Med Sci"},{"key":"3227_CR12","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2019.190428","author":"F Wang","year":"2020","unstructured":"Wang F, Ge A, Dai A et al (2020) Analysis of prostate-specific antigen-related indexes, neutrophil-to-lymphocyte ratio in patients with concurrent benign prostatic hyperplasia and histologic prostatitis. Clin Lab. https:\/\/doi.org\/10.7754\/Clin.Lab.2019.190428","journal-title":"Clin Lab"},{"issue":"6","key":"3227_CR13","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.eururo.2007.11.026","volume":"54","author":"JC Nickel","year":"2008","unstructured":"Nickel JC, Roehrborn CG, O\u2019Leary MP et al (2008) The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 54(6):1379\u20131384","journal-title":"Eur Urol"},{"issue":"16","key":"3227_CR14","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/pros.21027","volume":"69","author":"G Robert","year":"2009","unstructured":"Robert G, Descazeaud A, Nicola\u00efew N et al (2009) Inflammation in benign prostatic hyperplasia: a 282 patients\u2019 immunohistochemical analysis. Prostate 69(16):1774\u20131780. https:\/\/doi.org\/10.1002\/pros.21027","journal-title":"Prostate"},{"issue":"4","key":"3227_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.eururo.2014.06.026","volume":"66","author":"AR Zlotta","year":"2014","unstructured":"Zlotta AR, Egawa S, Pushkar D et al (2014) Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol 66(4):619\u2013622","journal-title":"Eur Urol"},{"issue":"19","key":"3227_CR16","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Evaluation, and Treatment of High B","year":"2001","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19):2486\u20132497","journal-title":"JAMA"},{"issue":"3","key":"3227_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/MOL.0b013e32832ac03e","volume":"20","author":"S Devaraj","year":"2009","unstructured":"Devaraj S, Singh U, Jialal I (2009) Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 20(3):182\u2013189","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"3227_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/pros.21425","volume":"72","author":"E Shankar","year":"2012","unstructured":"Shankar E, Vykhovanets EV, Vykhovanets OV et al (2012) High-fat diet activates pro-inflammatory response in the prostate through association of Stat-3 and NF-\u03baB. Prostate 72(3):233\u2013243. https:\/\/doi.org\/10.1002\/pros.21425","journal-title":"Prostate"},{"issue":"3","key":"3227_CR19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.eururo.2011.11.013","volume":"61","author":"C De Nunzio","year":"2012","unstructured":"De Nunzio C, Aronson W, Freedland SJ et al (2012) The correlation between metabolic syndrome and prostatic diseases. Eur Urol 61(3):560\u2013570","journal-title":"Eur Urol"},{"issue":"2","key":"3227_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrurol.2015.301","volume":"13","author":"L Vignozzi","year":"2016","unstructured":"Vignozzi L, Gacci M, Maggi M (2016) Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 13(2):108\u2013119","journal-title":"Nat Rev Urol"},{"issue":"5","key":"3227_CR21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.mehy.2007.08.022","volume":"70","author":"L Wang","year":"2008","unstructured":"Wang L, Yang JR, Yang LY et al (2008) Chronic inflammation in benign prostatic hyperplasia: implications for therapy. Med Hypotheses 70(5):1021\u20131023","journal-title":"Med Hypotheses"},{"issue":"1","key":"3227_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/pcan.2012.44","volume":"16","author":"M Gacci","year":"2013","unstructured":"Gacci M, Vignozzi L, Sebastianelli A et al (2013) Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 16(1):101\u2013106","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"3227_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1464-410X.2010.09598.x","volume":"107","author":"JL St Sauver","year":"2011","unstructured":"St Sauver JL, Jacobsen SJ, Jacobson DJ et al (2011) Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int 107(3):443\u2013450","journal-title":"BJU Int"},{"issue":"18","key":"3227_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015502","volume":"98","author":"X Yang","year":"2019","unstructured":"Yang X, Zhang Q, Jiang G et al (2019) The effects of statins on benign prostatic hyperplasia and the lower urinary tract symptoms: a meta-analysis. Medicine (Baltimore) 98(18):e15502","journal-title":"Medicine (Baltimore)"},{"issue":"4\u20135","key":"3227_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.diff.2011.06.001","volume":"82","author":"ID McLaren","year":"2011","unstructured":"McLaren ID, Jerde TJ, Bushman W (2011) Role of interleukins, IGF and stem cells in BPH. Differentiation 82(4\u20135):237\u2013243","journal-title":"Differentiation"},{"issue":"3","key":"3227_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2605.2009.00972.x","volume":"33","author":"B Fibbi","year":"2010","unstructured":"Fibbi B, Penna G, Morelli A et al (2010) Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 33(3):475\u2013488","journal-title":"Int J Androl"},{"key":"3227_CR27","first-page":"139","volume":"51","author":"FR Danesh","year":"2003","unstructured":"Danesh FR, Anel RL, Zeng L et al (2003) Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp (Warsz) 51:139\u2013148","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"6","key":"3227_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S1568-9972(03)00049-1","volume":"2","author":"BR Kwak","year":"2003","unstructured":"Kwak BR, Mulhaupt F, Mach F (2003) Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2(6):332\u2013338","journal-title":"Autoimmun Rev"},{"key":"3227_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2020.105735","volume":"122","author":"L Liberale","year":"2020","unstructured":"Liberale L, Carbone F, Montecucco F et al (2020) Statins reduce vascular inflammation in atherogenesis: A review of underlying molecular mechanisms. Int J Biochem Cell Biol 122:105735","journal-title":"Int J Biochem Cell Biol"},{"issue":"20","key":"3227_CR30","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1038\/sj.onc.1210943","volume":"27","author":"PJ Kaplan-Lefko","year":"2008","unstructured":"Kaplan-Lefko PJ, Sutherland BW, Evangelou AI et al (2008) Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis. Oncogene 27(20):2868\u20132876","journal-title":"Oncogene"},{"issue":"10","key":"3227_CR31","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1210\/me.2012-1079","volume":"26","author":"T Lu","year":"2012","unstructured":"Lu T, Lin WJ, Izumi K et al (2012) Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol Endocrinol 26(10):1707\u20131715","journal-title":"Mol Endocrinol"},{"issue":"8","key":"3227_CR32","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.3390\/ijms19082411","volume":"19","author":"A Cevenini","year":"2018","unstructured":"Cevenini A, Orr\u00f9 S, Mancini A et al (2018) Molecular signatures of the insulin-like growth factor 1-mediated epithelial-mesenchymal transition in breast, lung and gastric cancers. Int J Mol Sci 19(8):2411","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3227_CR33","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1734-1140(09)70117-3","volume":"61","author":"J Szkodzi\u0144ski","year":"2009","unstructured":"Szkodzi\u0144ski J, Romanowski W, Hudzik B et al (2009) Effect of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients. Pharmacol Rep 61(4):654\u2013664","journal-title":"Pharmacol Rep"},{"key":"3227_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ghir.2016.06.001","volume":"29","author":"K Bergen","year":"2016","unstructured":"Bergen K, Brismar K, Tehrani S (2016) High-dose atorvastatin is associated with lower IGF-1 levels in patients with type 1 diabetes. Growth Horm IGF Res 29:78\u201382","journal-title":"Growth Horm IGF Res"},{"issue":"2","key":"3227_CR35","first-page":"952","volume":"40","author":"F Liu","year":"2018","unstructured":"Liu F, Sun Y, Liu B et al (2018) Insulin-like growth factor-1 induces epithelial-mesenchymal transition in hepatocellular carcinoma by activating survivin. Oncol Rep 40(2):952\u2013958","journal-title":"Oncol Rep"},{"issue":"33","key":"3227_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016848","volume":"98","author":"L Yin","year":"2019","unstructured":"Yin L, Tang Y, Pan A et al (2019) The application of IL-10 and TNF-\u03b1 in expressed prostatic secretions and prostatic exosomal protein in urine in the diagnosis of patients with chronic prostatitis. Medicine (Baltimore) 98(33):e16848","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"3227_CR37","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.4314\/ahs.v20i3.31","volume":"20","author":"N Roya","year":"2020","unstructured":"Roya N, Fatemeh T, Faramarz MA et al (2020) Frequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia. Afr Health Sci 20(3):1264\u20131272","journal-title":"Afr Health Sci"},{"key":"3227_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.freeradbiomed.2020.11.032","volume":"162","author":"P Zhang","year":"2021","unstructured":"Zhang P, Zhang X, Huang Y et al (2021) Atorvastatin alleviates microglia-mediated neuroinflammation via modulating the microbial composition and the intestinal barrier function in ischemic stroke mice. Free Radic Biol Med 162:104\u2013117","journal-title":"Free Radic Biol Med"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03227-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03227-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03227-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T10:38:02Z","timestamp":1660214282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03227-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["3227"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03227-z","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"2 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The use of animals in this research was approved by the ethics committee of experimental animal of Anhui medical university.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}